BMYBristol-Myers SquibbNeutralBristol-Myers Squibb

9/1/2026 on

Is $CABA up today because they use a fully human scFv binder vs NVS and BMY? Not really trusting my AI queries on this topic.

IVVDInvivydBullishInvivyd

4/9/2026 on

Some thoughts on $IVVD today, since I haven't seen anyone mention this. This study upsizing today could be seen as concerning, but I think it was mostly expected by the market because of recent updates on covid incidence, and it seems the prudent thing to do. I have always thought IVD2311 would hit on efficacy, based on how all the preclinical data closely matches their marketed antibody Pemivibart. My concern has mostly been safety, because Pemivibart can cause anaphylaxis, and while moving to IM from IV theoretically should mitigate this (as well as next gen formulation), it was not for sure, and there could be other safety issues that arise. If this is going to be used as a prophylaxis, it needs to be squeaky clean. So I was pleased to hear this anecdote on the call, min 10:00 to 11:00: “… we have achieved alignment on a pediatric study plan that can enable us to seek BLA for VYD2311 for use in pediatric populations, ages 0-11. Encouragingly, while we proposed an age cohort de-escalation approach to the agency, they have responded by recommending a parallel group design including infants and babies in ages 0-2 to start, at the same time as other cohorts. This perspective, combined with recent feedback from our Declaration IDMC on broader subject eligibility for Declaration to include pregnant women, and the dropping certain safety check ins, certainly speaks to the increasing appreciation of the potential safety profile of low dose monoclonal antibodies by key counterparties.” I really don’t think they would expand to pregnant women / 0-2 year olds and drop safety check ins if they were seeing anaphylaxis, so I think this bodes very well for a clean safety profile. The wild card is mostly what will happen with Covid. If it continues to decline they may not get great powering for their study. It’s a risk, but efficacy should be strong so not sure how much risk. Overall, for me, because my bigger concern was safety, this update improved the risk reward equation at the current price quite a bit so I bought. I make these posts to challenge my thesis, and always appreciate any comments and arguments to the contrary.

Anyone else worried about GLP price wars? Recent NVO moves and results show steep price concessions, and while mounjaro / zepbound are better drugs, are they THAT much better? Plus some markets where semaglutide is off patent. Plus lots of other GLPs coming in a few years. Long story short (pun intended), is LLY a short here? Just a thought.

NeutralARWRArrowhead PharmaArrowhead PharmaWVEWAVE Life SciencesWAVE Life Sciences

1/6/2026 on

Still early days but one thing I like about the Activin E knockdown programs of $ARWR and $WVE are patients with severe obesity and diabetes are more likely to have a higher baseline Activin E phenotype. Not only does this mean that these knockdown drugs could have higher efficacy in these patients, but in the future I wonder if there could even be patient selection based on Activin E phenotype. I.e give INBHE to high Activin E phenotype patients and GLPs to others. Curious what other people think about this possibility.

A few thoughts about biotech in 2025 and ideas for 2026. $XBI $NBI